Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma S.A. (NASDAQ:IPHA ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Henry Wheeler - VP, IR and Communication Mondher Mahjoubi - CEO Sonia Quaratino - Chief Medical Officer Yannis Morel - EVP, BD and Product Portfolio Strategy Conference Call Participants Rabib Chaudhury - Leerink Partners Carly Kenselaar - Citi Arthur He - H.C.

Innate Pharma S.A. (IPHA) Q3 2023 Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its revenues and cash position for the first nine months of 2023. “With our strong cash position, we continue to execute against our strategy to develop innovative proprietary and partnered assets with key players. We look forward to this year's ASH Annual Meeting where we will present the final results of the lacutamab TELLOMAK Phase 2 study in patients with Séza.

Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2023. Participants during the call will be: Mondher Mahjoubi, Chief Executive Officer Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development Sonia Quaratino,.

Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces new clinical data for lacutamab and SAR443579/IPH6101 at ASH 2023.

Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. Jefferies London Healthcare Conference Event Date: November 15, 2023, London, UK 6th Annual Evercore ISI HealthCONx Conference Event Date: November 28, 2023, Miami, USA Investir Day Event Date: November 28, 2023, Paris, France About Innate Phar.

Innate Pharma Announces Its Participation to Upcoming Investor Conferences

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma 2024 Financial calendar.

Innate Pharma 2024 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place October 20-24 in Madrid, Spain. Abstract details: SAR'579 / IPH6101 (from a Joint Research Collaboration with Sanofi) Presentation Number: 823O Presentation Title: Preliminary Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis of.

Innate Pharma Announces Abstracts Selected for ESMO Congress 2023

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the lacutamab IND leading to a pause in new patient enrollment to the Company's ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL). The partial clinical hold follows one fatal case of hemophagocytic lymphohistiocytosis (HLH), a rare hematologic disor.

Innate Pharma Provides Update on Lacutamab Clinical Program

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced an encore presentation of interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides (MF) according to updated guidelines (Olsen 20221) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023, being held September 21-23, 2023 in Leiden, the Netherlands. The data confirms clinical activity and favorable safety profile of lacutam.

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma S.A. (NASDAQ:IPHA ) Q2 2023 Earnings Conference Call September 14, 2023 8:00 AM ET Company Participants Henry Wheeler - VP, IR & Communication Mondher Mahjoubi - CEO Joyson Karakunnel - Interim Chief Medical Officer Yannis Morel - EVP, BD and Product Portfolio Strategy Frederic Lombard - CFO Conference Call Participants Ashiq Mubarack - Citi Jingming Chen - Evercore ISI Daina Graybosch - Leerink Partners Operator Hello, and welcome to the Innate Pharma First Half 2023 Financial Results and Business Update Conference Call.

Innate Pharma S.A. (IPHA) Q2 2023 Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma reports first half 2023 financial results and business update.

Innate Pharma Reports First Half 2023 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. In addition, the Company will hold a conference call on Thursday, September 14, 2023, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2023. Citi's 18th Annual BioPharma Conference Event Date: Septemb.

Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the following upcoming conference: H.C. Wainwright Immune Cell Engager Virtual Conference Event Date: August 17 - virtual About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to.

Innate Pharma to Participate in Upcoming Investor Conference

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial (NCT05839626), evaluating SAR'514 / IPH6401 in relapsed/refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)1. SAR'514 is a trifunctional anti-BCMA NKp46xCD16 NK cell engager, using Sanofi's proprietary CROSSODILE® multi-functional platform, which.

First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in MATISSE, a Phase 2 multicenter single-arm study (NCT05742607), sponsored by Innate Pharma, evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung can.

First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides (MF) according to updated lymph node classification confirms clinical activity and favorable safety profile of lacutamab, an anti-KIR3DL2 antibody. The data were presented at the 17th International Conference on Malignant Lymphoma, in Lugano, Switzerland. As of March 4, 202.

Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that interim efficacy results from the TELLOMAK Phase 2 study of lacutamab in advanced Mycosis Fungoides will be presented at the 17th International Conference on Malignant Lymphoma, being held in Lugano, June 13 – 17, 2023. Efficacy results will be presented according to updated lymph node classification. Presentation details Title: Lacutamab in patients with adv.

Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that updated preclinical data on its IPH6501 tetra-specific ANKET® (Antibody-based Natural Killer cell Engager Therapeutics) are presented at the European Hematology Association (EHA) 2023 congress. IPH6501 is a first-in-class CD20-targeting tetra-specific ANKET® that co-engages two activating receptors (NKp46 and CD16), the interleukin-2 receptor (without involve.

Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress

Innate (IPHA) and Sanofi's SAR'579 / IPH6101 get Fast Track Designation in the United States for the treatment of hematological malignancies.

Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag

A therapy Innate Pharma and Sanofi are developing was granted Fast Track Designation by the FDA. Innate Pharma has enough cash to fund operations into 2025, it said.

Why Shares of Innate Pharma Jumped Thursday

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) is pleased to share Sanofi's news that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SAR'579 / IPH6101 for the treatment of hematological malignancies. Fast Track Designation is an FDA process designed to facilitate the development, and expedite the review of, medicines to treat serious conditions and fill unmet medical need. The FDA created t.

SAR'579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that the abstract entitled “A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia” was published on the ASCO 2023 Annual Meeting website. The abstract concludes that SAR'579, in development by Sanofi, was well tolerated up to doses of 3 mg/kg QW wi.

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the following upcoming conferences: American Society for Clinical Oncology (ASCO) 2023 Annual Meeting Event Date: June 2-5, Chicago (USA) Jefferies Healthcare Conference 2023 Event Date: June 7-9, New-York (USA) Goldman Sachs 44th Annual Global Healthcare Conference Event Date: June 12-15,.

Innate Pharma to Participate in Upcoming Investor Conferences

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data on its IPH6501 tetra-specific ANKET® (Antibody-based Natural Killer cell Engager Therapeutics) have been selected for oral presentation at the European Hematology Association (EHA) 2023 congress, being held 8 to 15 June 2023 in Frankfurt, Germany. ANKET® is Innate's proprietary platform for developing next-generation, multi-specific natur.

Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress

Innate Pharma SA (NASDAQ:IPHA ) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ET Company Participants Henry Wheeler - VP, IR & Communication Mondher Mahjoubi - Chairman & CEO Joyson Karakunnel - EVP & Chief Medical Officer Yannis Morel - EVP, Product Portfolio Strategy & Business Development Frederic Lombard - SVP & CFO Conference Call Participants Ashiq Mubarack - Citigroup Daina Graybosch - SVB Securities Swayampakula Ramakanth - H.C. Wainwright & Co. Justine Telliez - Kepler Cheuvreux Jingming Chen - Evercore ISI Operator Thank you for joining the Innate Pharma Publication of Revenue for First Quarter 2023 Conference Call.

News for Innate Pharma SA Stock (IPHA)